GSK’s fully liquid presentation of its meningococcal vaccine Menveo has been approved by the European Commission (EC) to ...
The EC has granted approval for presentation of GSK's Menveo vaccine (MenACWY) for invasive meningococcal disease (IMD).
The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...
GSK plc GSK announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children ...
GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease, IMD, caused by ...
London: GSK plc has announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of ...
In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis ...
European Commission approves GSK’s fully liquid Menveo meningococcal vaccine: London, UK Friday, November 29, 2024, 11:00 Hrs [IST] GSK plc announced that the European Commissio ...